Resource Center

New Castle, DE —December 5, 2024  —  ABS Bio, Inc., a leader in biospecimen sourcing, cell culture services and biostorage for the global pharmaceutical and biotechnology industry, today announced a strategic refresh of its corporate brand identity.

New Castle, DE — November 14, 2024  —  ABS Bio, Inc., a leader in biospecimen sourcing, cell culture services and biostorage for the global pharmaceutical and biotechnology industry, today announced a strategic investment by 3 Boomerang Capital, a Greenwich, CT based healthcare-focused private equity firm. The investment will position ABS Bio to accelerate enhancements to its service offerings while growing its reach among biopharma R&D professionals.  ABS also announced an expanded board of directors, including John Chickosky as Executive Chairman, and Greg Swanberg and Martin LeBlanc as Directors.

The journey from initial drug discovery to clinical application is full of challenges, especially during the pre-clinical phase. This critical stage, where potential drug candidates are rigorously tested for efficacy and safety, is essential for identifying viable therapies before they reach human trials. Despite its importance, pre-clinical drug discovery is often hampered by various bottlenecks that can impede progress and inflate costs. In this blog, we will explore common bottlenecks in pre-clinical drug discovery, their impact, and potential strategies to overcome them.